胸腺五肽辅助治疗社区获得性肺炎的疗效

Effect of Thymopentin on Community-Acquired Pneumonia

目的分析胸腺五肽辅助治疗社区获得性肺炎的疗效。方法选取2016年3月至2017年9月住院治疗的320例社区获得性肺炎患者,按随机数字表法将其分为对照组和观察组,每组160例。对照组予常规内科治疗,观察组在此基础上肌内注射胸腺五肽。比较2组的临床疗效、症状体征恢复时间、达出院标准时间、T细胞亚群(CD4+、CD8+、CD4+/CD8+)变化及不良反应等。结果观察组总有效率为93.13%,高于对照组的84.38%(P<0.05);观察组退热时间、啰音消失时间、达出院标准时间分别为(2.16±0.87)d、(4.38±1.00)d、(6.99±1.51)d均短于对照组的(2.54±0.84)d、(4.81±1.39)d、(7.57±1.29)d,差异有统计学意义(P<0.05);治疗后观察组免疫水平优于对照组(P<0.05)。治疗过程中未见严重不良反应。结论胸腺五肽可以显著改善社区获得性肺炎患者免疫功能,提高其临床疗效,安全性亦较高。

Objective To analyze the clinical effect of thymopentin as an adjuvant on community-acquired pneumonia(CAP).Methods From Mar2016to Sep2017,320patients with CAP were randomly given routine treatment alone(control group,n=160)or in combination with intramuscular injection of thymopentin(observation group,n=160).Clinical efficacy,time to recovery of symptoms and signs,time to reaching discharge standard,changes in T-lymphocyte subsets(CD4^+、CD8^+、CD4^+/CD8^+)and adverse reactions were compared between the two groups.Results The total effective rate in observation group(93.13%)was higher than that in control group(84.38%)(P<0.05).The fever subsidence time,rale disappearance time and time to reaching discharge standard in observation group were respectively(2.16±0.87),(4.38±1.00)and(6.99±1.51)days,which were shorter than those in control group((2.54±0.84),(4.81±1.39)and(7.57±1.29)days,respectively)(P<0.05).In addition,the immune level in observation group was higher than that in control group(P<0.05).No severe adverse reactions were found during treatment.Conclusion Thymopentin treatment can effectively and safely improve the immunologic function in patients with CAP.